IPH5201 as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.

Trial Identifier: D6770C00001
Sponsor: MedImmune, LLC
NCTID:: NCT04261075
Start Date: March 2020
Primary Completion Date: June 2022
Study Completion Date: June 2022
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CH Lausanne, CH, 1011
ES Barcelona, ES, 8035
ES Madrid, ES, 28027
FR BORDEAUX CEDEX, FR, 33076
FR Villejuif, FR, 94805
US, NC Huntersville, NC, US, 28078
US, RI Providence, RI, US, 02906
US, TN Nashville, TN, US, 37203